Q-omics provides the consensus-scored EDDM3B profile across patient tissues and cancer cell-line models. EDDM3B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, EDDM3B is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, EDDM3B RNA expression shows 6,596 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KICH, KIRC, and LUAD as cancer lineages where EDDM3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDDM3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDDM3B survival associations across molecular data types. EDDM3B RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDDM3B RNA expression–survival associations across cancer types. High EDDM3B expression shows unfavorable associations in KICH, THCA, ESCA and THYM, but favorable associations in BRCA and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for EDDM3B RNA expression.
This table summarizes EDDM3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EDDM3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDDM3B shows lower tumor expression in KIRC, KIRP, PRAD, LUSC and KICH and higher tumor expression in BRCA. The KIRC box plot shows higher EDDM3B RNA expression in normal versus tumor tissue (log2 FC = −0.027, t-test p < 0.001).
This table shows molecular features associated with EDDM3B in patient tissues and cancer cell lines. In patient samples, EDDM3B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, EDDM3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
